Applied Filters
E+F patent attorney elevated to partner
Elkington + Fife has unveiled Mark Scott as a new partner in the UK firm’s patent practice.
Novartis to boost eye care portfolio with $3.4bn buy
Novartis is set to acquire assets associated with Xiidra ((lifitegrast ophthalmic solution), a dry eye treatment, from Takeda.
NHS partners with drugmakers to eliminate hep C
The National Health Service, the UK’s government-run health system, has partnered with Gilead Sciences, Merck Sharp and Dohme and AbbVie to help eliminate hepatitis C in England.
AstraZeneca partners on AI drug discovery collaboration
AstraZeneca has begun collaborating with UK-headquartered artificial intelligence company BenevolentAI to use AI and machine learning for the discovery and development of new treatments.
EU complains to WTO over Turkey’s pharma measures
The European Union has asked the World Trade Organization to initiate dispute consultations with Turkey over requirements imposed by the country on pharmaceutical products.
EPO president refers plant patentability decision for appeal
European Patent Office president António Campinos will refer a recent decision on the patentability of exclusively obtained by essentially biological processes to the office’s Enlarged Board of Appeal.
Eli Lilly defeat shows one size does not fit all in obviousness test: lawyers
The UK Supreme Court’s decision in Actavis v Eli Lilly confirms that a multi-factorial judgement should be used to determine whether an invention is obvious or not, lawyers have told WIPR.
Cancer Research UK forms immunotherapy alliance
Cancer Research UK has formed a multimillion-pound drug discovery alliance with fellow charity LifeArc and Japanese company Ono Pharmaceutical.
UK biotech R&D up 65% since 2016, says report
A “biotech boom” is underway in the UK, according to a new report from UK investment management firm Downing.
WHO to begin working on gene editing research registry
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
